Parkinsons Treatment Market: By Drug Class, Dopamine Precursors, Catechol-o-methyltransferase Inhibitors, Peripheral Decarboxylase Inhibitors, Others ), By Distribution Channel and By Region Forecast 2019-2030
Parkinsons Treatment Market size was valued at US$ 4,482.4 million in 2023, growing at a CAGR of 12.4% from 2024 to 2030. By drug class, the global market has been segmented into Monoamine Oxidase Inhibitors (MAO), Dopamine Precursors, Catechol-o-methyltransferase Inhibitors (COMT), Peripheral Decarboxylase Inhibitors, Others (Anticholinergics, Antihistaminics). The Peripheral Decarboxylase Inhibitors segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. It is attributed to the potency of the drug than other class of drugs. Based on distribution channel, the global market is segmented into Hospital Pharmacies, Online Pharmacies, Retail Pharmacies. Among these, the Hospital Pharmacies segment is expected to have the fastest-growing market during the forecast period 2023-2029
According to Precision Business Insights. It is due to the large patient base in the hospital which makes high demand in hospital pharmacies. Also, the growing number of patient visits to the hospital due to the availability of diagnostic laboratories and skilled professionals and doctors. parkinsons disease is the chronic, progressive neurodegenerative disorder that can be characterized by rigidity, tremors, postural instability and bradykinesia (slowness of movement). In Parkinson disorder, patients can also experience significant non-motor symptoms like changes in the sleep disturbances, autonomic erectile dysfunction and cognition and mood swings. The condition is attributed to the degeneration of the dopamine-producing cells of the substantia nigra.
Study Period
2024-2030Base Year
2023CAGR
12.4%Largest Market
North-AmericaFastest Growing Market
North-America
Growing advancements in the treatment is anticipated to propel the market growth over the forecast years. Moreover, the increasing geriatric population, increasing prevalence of Parkinson disease around the globe, treatment affordability are boosting the global market growth over the forecast years.
By region, the North America is expected to witness the highest market share during the forecast period it holds a tremendous potential market for global parkinsons treatment.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 4,482.4 million |
|
Market CAGR |
12.4% |
|
By Drug Class |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The parkinsons treatment market size was valued at US$ 4,482.4 million in 2023, growing at a CAGR of 12.4% from 2024 to 2030
New products and therapy launch especially research on gene therapy are trending in the global market which will further drive the market growth in the forecasted years.
The shift towards research activities from symptomatic treatment to Parkinson disorder modifying treatment will create lucrative growth in the global market.
Present of alternatives are the major restraining factors in the global market.
| 1. Executive Summary |
| 2. Global Parkinsons Treatment Market Introduction |
| 2.1.Global Parkinsons Treatment Market - Taxonomy |
| 2.2.Global Parkinsons Treatment Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3. Global Parkinsons Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Parkinsons Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Parkinsons Treatment Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Monoamine Oxidase Inhibitors (MAO) |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Dopamine Precursors |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Catechol-o-methyltransferase Inhibitors (COMT) |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Peripheral Decarboxylase Inhibitors |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others (Anticholinergics, Antihistaminics) |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Parkinsons Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Online Pharmacies |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Retail Pharmacies |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Parkinsons Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. North America Parkinsons Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Monoamine Oxidase Inhibitors (MAO) |
| 8.1.2.Dopamine Precursors |
| 8.1.3.Catechol-o-methyltransferase Inhibitors (COMT) |
| 8.1.4.Peripheral Decarboxylase Inhibitors |
| 8.1.5.Others (Anticholinergics, Antihistaminics) |
| 8.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacies |
| 8.2.2.Online Pharmacies |
| 8.2.3.Retail Pharmacies |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9. Europe Parkinsons Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Monoamine Oxidase Inhibitors (MAO) |
| 9.1.2.Dopamine Precursors |
| 9.1.3.Catechol-o-methyltransferase Inhibitors (COMT) |
| 9.1.4.Peripheral Decarboxylase Inhibitors |
| 9.1.5.Others (Anticholinergics, Antihistaminics) |
| 9.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacies |
| 9.2.2.Online Pharmacies |
| 9.2.3.Retail Pharmacies |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10. Asia Pacific (APAC) Parkinsons Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Monoamine Oxidase Inhibitors (MAO) |
| 10.1.2.Dopamine Precursors |
| 10.1.3.Catechol-o-methyltransferase Inhibitors (COMT) |
| 10.1.4.Peripheral Decarboxylase Inhibitors |
| 10.1.5.Others (Anticholinergics, Antihistaminics) |
| 10.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacies |
| 10.2.2.Online Pharmacies |
| 10.2.3.Retail Pharmacies |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11. Middle East and Africa (MEA) Parkinsons Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Monoamine Oxidase Inhibitors (MAO) |
| 11.1.2.Dopamine Precursors |
| 11.1.3.Catechol-o-methyltransferase Inhibitors (COMT) |
| 11.1.4.Peripheral Decarboxylase Inhibitors |
| 11.1.5.Others (Anticholinergics, Antihistaminics) |
| 11.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacies |
| 11.2.2.Online Pharmacies |
| 11.2.3.Retail Pharmacies |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12. Latin America Parkinsons Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Monoamine Oxidase Inhibitors (MAO) |
| 12.1.2.Dopamine Precursors |
| 12.1.3.Catechol-o-methyltransferase Inhibitors (COMT) |
| 12.1.4.Peripheral Decarboxylase Inhibitors |
| 12.1.5.Others (Anticholinergics, Antihistaminics) |
| 12.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacies |
| 12.2.2.Online Pharmacies |
| 12.2.3.Retail Pharmacies |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Salix Pharmaceuticals (U.S.) |
| 13.2.2.GlaxoSmithKline Plc. (U.K.) |
| 13.2.3.Wockhardt Limited (India) |
| 13.2.4.Impax Laboratories, Inc. (U.S) |
| 13.2.5.Novartis AG (Switzerland) |
| 13.2.6.Mylan N.V (U.S) |
| 13.2.7.Teva Pharmaceutical Industries Ltd.(Israel) |
| 13.2.8.Cipla Inc.(India) |
| 13.2.9.Par Pharmaceutical (U.S) |
| 13.2.10.Apotex Inc (Canada) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
